Irina Staatz-Granzer
Chairman at INNATE PHARMA
Net worth: 59 231 $ as of 31/03/2024
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Pier Vincenzo Piazza | M | 63 | 11 years | |
Hervé Eloi Dominique Brailly | M | 62 | 25 years | |
Yannis Morel | M | 50 | 23 years | |
Odile Belzunce | F | 44 | 19 years | |
Véronique Chabernaud | M | 62 | 9 years | |
Peter Neubeck | M | - |
Emergence Therapeutics AG
Emergence Therapeutics AG Pharmaceuticals: MajorHealth Technology Emergence Therapeutics AG is biopharmaceutical company. It develops novel antibody drug conjugate. The company was founded by Jack Elands and Xavier Preville and is headquartered in Duisburg, Germany. | 5 years |
Xavier Preville | M | - |
Emergence Therapeutics AG
Emergence Therapeutics AG Pharmaceuticals: MajorHealth Technology Emergence Therapeutics AG is biopharmaceutical company. It develops novel antibody drug conjugate. The company was founded by Jack Elands and Xavier Preville and is headquartered in Duisburg, Germany. | - |
Karina Hansen | M | 51 | 2 years | |
Eric Vivier | M | 60 | 25 years | |
Pascale Boissel | F | 57 | 4 years | |
Karen Linehan | F | 65 | 2 years | |
Henry Wheeler | M | 40 | 3 years | |
Claire de Saint Blanquat | F | 51 | 4 years | |
Jack Elands | M | - |
Emergence Therapeutics AG
Emergence Therapeutics AG Pharmaceuticals: MajorHealth Technology Emergence Therapeutics AG is biopharmaceutical company. It develops novel antibody drug conjugate. The company was founded by Jack Elands and Xavier Preville and is headquartered in Duisburg, Germany. | - |
Olivier Martinez | M | 54 | 14 years | |
Gilles Brisson | M | 72 | 17 years | |
Jean-Yves Blay | M | 61 | 7 years | |
Nicola Beltraminelli | M | 54 | 2 years | |
Guillaume Gimonet | M | - | - | |
Marie Line Lefevre | F | - | - | |
Stéphanie Monlezun | M | - | - | |
Léa Floquet | F | - | 3 years | |
Brahim Guetarni | M | 47 | 3 years | |
Frederic Lombard | M | 49 | 3 years | |
Sonia Quaratino | M | - | 1 years | |
Anders Gersel Pedersen | M | 73 | 4 years | |
Roy Amariglio | M | - |
Emergence Therapeutics AG
Emergence Therapeutics AG Pharmaceuticals: MajorHealth Technology Emergence Therapeutics AG is biopharmaceutical company. It develops novel antibody drug conjugate. The company was founded by Jack Elands and Xavier Preville and is headquartered in Duisburg, Germany. | - |
Matthew Hammond | M | 35 |
Emergence Therapeutics AG
Emergence Therapeutics AG Pharmaceuticals: MajorHealth Technology Emergence Therapeutics AG is biopharmaceutical company. It develops novel antibody drug conjugate. The company was founded by Jack Elands and Xavier Preville and is headquartered in Duisburg, Germany. | - |
Ohad Hammer | M | - |
Emergence Therapeutics AG
Emergence Therapeutics AG Pharmaceuticals: MajorHealth Technology Emergence Therapeutics AG is biopharmaceutical company. It develops novel antibody drug conjugate. The company was founded by Jack Elands and Xavier Preville and is headquartered in Duisburg, Germany. | - |
Odile Laurent | F | 63 | 7 years | |
Marc Voigt | M | 51 |
Pharma-Lizenz-Club Deutschland
| - |
Heiner Pieper | M | - |
Pharma-Lizenz-Club Deutschland
| - |
Bernd Mühlenweg | M | 52 |
Pharma-Lizenz-Club Deutschland
| - |
Luc St-Onge | M | 58 |
Pharma-Lizenz-Club Deutschland
| - |
Arsène Guekam | M | - | - | |
Arvind Sood | M | - | - | |
Sally Bennett | M | 52 | 2 years | |
Aristotelis Nastos | M | 56 |
Emergence Therapeutics AG
Emergence Therapeutics AG Pharmaceuticals: MajorHealth Technology Emergence Therapeutics AG is biopharmaceutical company. It develops novel antibody drug conjugate. The company was founded by Jack Elands and Xavier Preville and is headquartered in Duisburg, Germany. | - |
François Thomas | M | 66 | 2 years | |
Helle Mengel | M | - | - |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Pierre F. Dodion | M | 69 | 6 years | |
François Romagné | M | 60 | 14 years | |
Philippe Pouletty | M | 65 | 15 years | |
Peter Petzelbauer | M | - |
FIBREX Medical, Inc.
FIBREX Medical, Inc. Miscellaneous Commercial ServicesCommercial Services FIBREX Medical Inc. is a development stage bio-pharmaceutical company. Its operational affiliate FIBREX Medical Research & Development GmbH was established in Vienna in February 2001. The company was founded to convert high impact scientific discovery into pharmaceutical products for important diseases. The company aims to become a leader in the development and commercialization of pharmaceuticals targeting fundamental mechanisms of inflammation and tissue injury. While inflammation is highly desirable to defend the organism against foreign particles and infections, it can become harmful and destructive if it runs unchecked. Inflammation-based tissue injury is well known as a major component in the pathogenesis and progression of important diseases such as myocardial infarction, septic and hemorrhagic shock, graft rejection, or rheumatoid arthritis. In addition, endothelial dysfunction in inflamed tissues leads to capillary leak and deleterious edema formation, aggravating organ dysfunction. | 12 years |
Regina Hodits | M | 53 |
FIBREX Medical, Inc.
FIBREX Medical, Inc. Miscellaneous Commercial ServicesCommercial Services FIBREX Medical Inc. is a development stage bio-pharmaceutical company. Its operational affiliate FIBREX Medical Research & Development GmbH was established in Vienna in February 2001. The company was founded to convert high impact scientific discovery into pharmaceutical products for important diseases. The company aims to become a leader in the development and commercialization of pharmaceuticals targeting fundamental mechanisms of inflammation and tissue injury. While inflammation is highly desirable to defend the organism against foreign particles and infections, it can become harmful and destructive if it runs unchecked. Inflammation-based tissue injury is well known as a major component in the pathogenesis and progression of important diseases such as myocardial infarction, septic and hemorrhagic shock, graft rejection, or rheumatoid arthritis. In addition, endothelial dysfunction in inflamed tissues leads to capillary leak and deleterious edema formation, aggravating organ dysfunction. | - |
Stéphane Boissel | M | 56 | 8 years | |
Joël Jean-Louis Besse | M | - |
FIBREX Medical, Inc.
FIBREX Medical, Inc. Miscellaneous Commercial ServicesCommercial Services FIBREX Medical Inc. is a development stage bio-pharmaceutical company. Its operational affiliate FIBREX Medical Research & Development GmbH was established in Vienna in February 2001. The company was founded to convert high impact scientific discovery into pharmaceutical products for important diseases. The company aims to become a leader in the development and commercialization of pharmaceuticals targeting fundamental mechanisms of inflammation and tissue injury. While inflammation is highly desirable to defend the organism against foreign particles and infections, it can become harmful and destructive if it runs unchecked. Inflammation-based tissue injury is well known as a major component in the pathogenesis and progression of important diseases such as myocardial infarction, septic and hemorrhagic shock, graft rejection, or rheumatoid arthritis. In addition, endothelial dysfunction in inflamed tissues leads to capillary leak and deleterious edema formation, aggravating organ dysfunction. | - |
Ekaterina Smirnyagina | M | 58 | - | |
Patrick J. Langlois | M | 78 | 12 years | |
Marcel Rozencweig | M | 78 | 8 years | |
Laure-Hélène Mercier | F | 46 | 14 years | |
Tracy Rossin | F | 46 | 3 years | |
Marcus Schindler | M | 57 | 3 years | |
Lars Fruergaard Jorgensen | M | 58 | 6 years | |
Joyson Karakunnel | M | 54 | 3 years | |
Jean-Charles Soria | M | 53 | - | |
Michael A. Caligiuri | M | 68 | - | |
Nicolai Wagtmann | M | 60 | 3 years | |
Frédérique Brune | M | 58 | - | |
Mondher Mahjoubi | M | 65 | 8 years | |
Karsten Munk Knudsen | M | 53 | - | |
Danielle Spangler | F | - | - | |
Per Gunnar Falk | M | - | - | |
Anne-Sophie Herelle | F | 43 | - | |
Catherine Moukheibir | F | 64 | 5 years | |
Maïlys Ferrère | F | 60 | 4 years | |
Bernard Geudelin | M | - |
FIBREX Medical, Inc.
FIBREX Medical, Inc. Miscellaneous Commercial ServicesCommercial Services FIBREX Medical Inc. is a development stage bio-pharmaceutical company. Its operational affiliate FIBREX Medical Research & Development GmbH was established in Vienna in February 2001. The company was founded to convert high impact scientific discovery into pharmaceutical products for important diseases. The company aims to become a leader in the development and commercialization of pharmaceuticals targeting fundamental mechanisms of inflammation and tissue injury. While inflammation is highly desirable to defend the organism against foreign particles and infections, it can become harmful and destructive if it runs unchecked. Inflammation-based tissue injury is well known as a major component in the pathogenesis and progression of important diseases such as myocardial infarction, septic and hemorrhagic shock, graft rejection, or rheumatoid arthritis. In addition, endothelial dysfunction in inflamed tissues leads to capillary leak and deleterious edema formation, aggravating organ dysfunction. | - |
Katherine Brandl | F | - |
FIBREX Medical, Inc.
FIBREX Medical, Inc. Miscellaneous Commercial ServicesCommercial Services FIBREX Medical Inc. is a development stage bio-pharmaceutical company. Its operational affiliate FIBREX Medical Research & Development GmbH was established in Vienna in February 2001. The company was founded to convert high impact scientific discovery into pharmaceutical products for important diseases. The company aims to become a leader in the development and commercialization of pharmaceuticals targeting fundamental mechanisms of inflammation and tissue injury. While inflammation is highly desirable to defend the organism against foreign particles and infections, it can become harmful and destructive if it runs unchecked. Inflammation-based tissue injury is well known as a major component in the pathogenesis and progression of important diseases such as myocardial infarction, septic and hemorrhagic shock, graft rejection, or rheumatoid arthritis. In addition, endothelial dysfunction in inflamed tissues leads to capillary leak and deleterious edema formation, aggravating organ dysfunction. | - |
Sonja Reingruber | M | - |
FIBREX Medical, Inc.
FIBREX Medical, Inc. Miscellaneous Commercial ServicesCommercial Services FIBREX Medical Inc. is a development stage bio-pharmaceutical company. Its operational affiliate FIBREX Medical Research & Development GmbH was established in Vienna in February 2001. The company was founded to convert high impact scientific discovery into pharmaceutical products for important diseases. The company aims to become a leader in the development and commercialization of pharmaceuticals targeting fundamental mechanisms of inflammation and tissue injury. While inflammation is highly desirable to defend the organism against foreign particles and infections, it can become harmful and destructive if it runs unchecked. Inflammation-based tissue injury is well known as a major component in the pathogenesis and progression of important diseases such as myocardial infarction, septic and hemorrhagic shock, graft rejection, or rheumatoid arthritis. In addition, endothelial dysfunction in inflamed tissues leads to capillary leak and deleterious edema formation, aggravating organ dysfunction. | - |
Rainer Henning | M | - |
FIBREX Medical, Inc.
FIBREX Medical, Inc. Miscellaneous Commercial ServicesCommercial Services FIBREX Medical Inc. is a development stage bio-pharmaceutical company. Its operational affiliate FIBREX Medical Research & Development GmbH was established in Vienna in February 2001. The company was founded to convert high impact scientific discovery into pharmaceutical products for important diseases. The company aims to become a leader in the development and commercialization of pharmaceuticals targeting fundamental mechanisms of inflammation and tissue injury. While inflammation is highly desirable to defend the organism against foreign particles and infections, it can become harmful and destructive if it runs unchecked. Inflammation-based tissue injury is well known as a major component in the pathogenesis and progression of important diseases such as myocardial infarction, septic and hemorrhagic shock, graft rejection, or rheumatoid arthritis. In addition, endothelial dysfunction in inflamed tissues leads to capillary leak and deleterious edema formation, aggravating organ dysfunction. | - |
Frank Morich | M | 69 | 6 years | |
Hemanshu Shah | M | 63 | 2 years | |
Terje Kalland | M | 73 | 3 years | |
Jean Deleage | M | 83 | 9 years | |
Jennifer Butler | F | - | 2 years |
Statistics
Country | Connections | % of total |
---|---|---|
France | 57 | 76.00% |
Germany | 11 | 14.67% |
Austria | 7 | 9.33% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Irina Staatz-Granzer
- Personal Network